Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12738753rdf:typepubmed:Citationlld:pubmed
pubmed-article:12738753lifeskim:mentionsumls-concept:C0205474lld:lifeskim
pubmed-article:12738753lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:12738753lifeskim:mentionsumls-concept:C0020474lld:lifeskim
pubmed-article:12738753lifeskim:mentionsumls-concept:C0085202lld:lifeskim
pubmed-article:12738753lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:12738753lifeskim:mentionsumls-concept:C1328885lld:lifeskim
pubmed-article:12738753pubmed:issue11lld:pubmed
pubmed-article:12738753pubmed:dateCreated2003-6-13lld:pubmed
pubmed-article:12738753pubmed:abstractTextApolipoprotein A-II (apoA-II) is a major protein on high-density lipoprotein (HDL) particles, and in mice, its levels are associated with triglyceride and glucose metabolism. In particular, transgenic mice overexpressing apoA-II exhibit hypertriglyceridemia, increased body fat, and insulin resistance, whereas apoA-II-null mice have decreased triglycerides and increased insulin sensitivity. Given the phenotypic overlap between familial combined hyperlipidemia (FCH) and apoA-II transgenic mice, we investigated the relationship of apoA-II to this disorder. Despite having lower HDL-cholesterol (HDL-C), FCH subjects had higher apoA-II levels compared with unaffected relatives (P<0.00016). Triglyceride and HDL-C levels were significant predictors of apoA-II, demonstrating that apoA-II variation is associated with several FCH-related traits. After adjustment for multiple covariates, there was evidence for the heritability of apoA-II levels (h2=0.15; P<0.02) in this sample. A genome scan for apoA-II levels identified significant evidence (LOD=3.1) for linkage to a locus on chromosome 1q41, coincident with a suggestive linkage for triglycerides (LOD score=1.4). Thus, this locus may have pleiotropic effects on apoA-II and FCH traits. Our results demonstrate that apoA-II is biochemically and genetically associated with FCH and may serve as a useful marker for understanding the mechanism by which FCH develops.lld:pubmed
pubmed-article:12738753pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12738753pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12738753pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12738753pubmed:languageenglld:pubmed
pubmed-article:12738753pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12738753pubmed:citationSubsetIMlld:pubmed
pubmed-article:12738753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12738753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12738753pubmed:statusMEDLINElld:pubmed
pubmed-article:12738753pubmed:monthJunlld:pubmed
pubmed-article:12738753pubmed:issn1524-4571lld:pubmed
pubmed-article:12738753pubmed:authorpubmed-author:CantorRita...lld:pubmed
pubmed-article:12738753pubmed:authorpubmed-author:CastellaniLaw...lld:pubmed
pubmed-article:12738753pubmed:authorpubmed-author:LusisAldons...lld:pubmed
pubmed-article:12738753pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:12738753pubmed:authorpubmed-author:AllayeeHooman...lld:pubmed
pubmed-article:12738753pubmed:issnTypeElectroniclld:pubmed
pubmed-article:12738753pubmed:day13lld:pubmed
pubmed-article:12738753pubmed:volume92lld:pubmed
pubmed-article:12738753pubmed:ownerNLMlld:pubmed
pubmed-article:12738753pubmed:authorsCompleteYlld:pubmed
pubmed-article:12738753pubmed:pagination1262-7lld:pubmed
pubmed-article:12738753pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:12738753pubmed:meshHeadingpubmed-meshheading:12738753...lld:pubmed
pubmed-article:12738753pubmed:meshHeadingpubmed-meshheading:12738753...lld:pubmed
pubmed-article:12738753pubmed:meshHeadingpubmed-meshheading:12738753...lld:pubmed
pubmed-article:12738753pubmed:meshHeadingpubmed-meshheading:12738753...lld:pubmed
pubmed-article:12738753pubmed:meshHeadingpubmed-meshheading:12738753...lld:pubmed
pubmed-article:12738753pubmed:meshHeadingpubmed-meshheading:12738753...lld:pubmed
pubmed-article:12738753pubmed:meshHeadingpubmed-meshheading:12738753...lld:pubmed
pubmed-article:12738753pubmed:meshHeadingpubmed-meshheading:12738753...lld:pubmed
pubmed-article:12738753pubmed:year2003lld:pubmed
pubmed-article:12738753pubmed:articleTitleBiochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia.lld:pubmed
pubmed-article:12738753pubmed:affiliationDepartment of Human Genetics, Gonda Genetics Research Center, of California, Los Angeles, Calif 90095, USA. hallayee@ucla.edulld:pubmed
pubmed-article:12738753pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12738753pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12738753pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:336entrezgene:pubmedpubmed-article:12738753lld:entrezgene
entrez-gene:25649entrezgene:pubmedpubmed-article:12738753lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12738753lld:entrezgene
lhgdn:association:35147lhgdn:found_inpubmed-article:12738753lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12738753lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12738753lld:pubmed